Table 2 Clinical demographic of patient participants for each stage of the study

Performance status

 0%(n)

52.94% (9)

45.45% (5)

16.67% (1)

48.48% (64)

48.77% (79)

54.54% (6)

59.1% (13)

 1%(n)

47.06% (8)

54.55% (6)

66.67% (4)

51.52% (68)

51.23% (83)

45.45% (5)

40.9% (9)

Participated in a trial (phase 1–3) before % (n)

22.73% (5)

25.00% (3)

20.00% (1)

15.43% (25)

20.99% (34)

0%

17.39% (4)

Trial Phase

 Screen fail

9.09% (2)

-

-

5.56% (9)

-

-

-

 Decline to participate in trial

-

-

-

0.62% (1)

-

-

-

 Phase 1

50.00% (13)

50% (6)

40% (2)

45.06% (72)

41.36% (67)

45.5% (5)

34.78% (8)

 Phase 2

31.82% (7)

50% (6)

60% (3)

44.44% (72)

58.64% (95)

54.5.% (6)

65.22% (15)

 Non-treatment trial (i.e. Target molecular)

9.09% (2)

-

-

4.32% (7)

-

-

-

Time on trial (< 1 year)

54.55% (12)

50% (6)

40% (2)

100% (162)

76.54% (124)

100% (11)

8.69% (2)

Disease group

 Breast

31.82% (7)

-

-

17.90% (29)

21.6% (35)

9.09% (1)

-

 Brain

-

-

-

17.90% (29)

6.80% (11)

-

-

 Lower GI

13.64% (3)

16.67% (2)

-

12.97% (21)

6.20% (10)

9.09% (1)

8.70% (2)

 Upper GI

-

-

-

5.65% (9)

2.47% (4)

27.27% (3)

17.39% (4)

 Gynaecology

-

-

-

9.26% (16)

-

18.18% (2)

30.43% (7)

 Head & Neck

-

8.33% (1)

-

6.79% (11)

3.70% (6)

9.09% (1)

 Haematological

9.09% (2)

8.33% (1)

1.23% (2)

4.94% (8)

9.09% (1)

13.04% (3)

 HPB

20.00% (1)

3.70% (6)

1.24% (2)

-

-

 Lung

22.73% (5)

16.67% (2)

20.00% (1)

19.14% (31)

16.67% (27)

9.09% (1)

 Lymphoma

18.18% (4)

41.67% (5)

60.00% (3)

4.94% (8)

9.25% (15)

-

8.70% (2)

 Melanoma

-

-

-

1.85% (3)

2.47% (4)

-

4.35% (1)

 Genitourinary (GU, excluding prostate)

4.55% (1)

8.33% (1)

-

-

1.85% (3)

-

-

 Prostate

-

-

-

7.41% (12)

4.94% (8)

-

-

 Sarcoma

-

-

-

1.23% (2)

0.62% (1)

9.09% (1)

17.39% (4)

 Thymus

-

-

-

-

0.62% (1)

-

-

 Unknown primary source

-

-

-

3.09% (5)

2.47% (4)

-

-